
Patrick Forde/Facebook
Apr 12, 2025, 03:13
Patrick Forde: Big News in Small Cell Lung Cancer: Tarlatamab Improves Survival vs. 2nd Line Chemo
Patrick Forde, Professor at The Johns Hopkins University, shared a post on X:
“Big news in small cell lung cancer, a disease which historically has had a very poor prognosis. The T cell engager, tarlatamab improves survival vs. 2nd line chemo. Hope is that durable responses will be seen and early phase data were encouraging.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 12:02
Apr 15, 2025, 11:54
Apr 15, 2025, 11:52
Apr 15, 2025, 11:46